SARS-CoV-2 immunochromatographic IgM/IgG rapid test in pregnancy: A false friend?
Fabre, M. ; Ruiz-Martinez, S. ; Monserrat Cantera, M.E. ; Cortizo Garrido, A. ; Beunza Fabra, Z. ; Peran, M. ; Benito, R. (Universidad de Zaragoza) ; Mateo, P. (Universidad de Zaragoza) ; Paules, C. (Universidad de Zaragoza) ; Oros, D. (Universidad de Zaragoza)
Resumen: Background: An increasing body of evidence has revealed that SARS-CoV-2 infection in pregnant women could increase the risk of adverse maternal and fetal outcomes. Careful monitoring of pregnancies with COVID-19 and measures to prevent neonatal infection are warranted. Therefore, rapid antibody tests have been suggested as an efficient screening tool during pregnancy.
Cases: We analysed the clinical performance during pregnancy of a rapid, lateral-flow immunochromatographic assay for qualitative detection of SARS-CoV-2 IgG/IgM antibodies. We performed a universal screening including 169 patients during their last trimester of pregnancy. We present a series of 14 patients with positive SARS-CoV-2 immunochromatographic assay rapid test result. Immunochromatographic assay results were always confirmed by chemiluminescent microparticle immunoassays for quantitative detection of SARS-CoV-2 IgG and IgM+IgA antibodies as the gold standard. We observed a positive predictive value of 50% and a false positive rate of 50% in pregnant women, involving a significantly lower diagnostic performance than reported in non-pregnant patients.
Discussion: Our data suggest that although immunochromatographic assay rapid tests may be a fast and profitable screening tool for SARS-CoV-2 infection, they may have a high false positive rate and low positive predictive value in pregnant women. Therefore, immunochromatographic assay for qualitative detection of SARS-CoV-2 IgG/IgM antibodies must be verified by other test in pregnant patients.
Idioma: Inglés
DOI: 10.1177/0004563220980495
Año: 2020
Publicado en: ANNALS OF CLINICAL BIOCHEMISTRY 58, 2 (2020), 149-152
ISSN: 0004-5632
Factor impacto JCR: 2.057 (2020)
Categ. JCR: MEDICAL LABORATORY TECHNOLOGY rank: 20 / 29 = 0.69 (2020) - Q3 - T3
Factor impacto SCIMAGO: 0.6 - Medicine (miscellaneous) (Q2) - Clinical Biochemistry (Q2)
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/CM18-00202
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/JR19-00006
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Microbiología (Dpto. Microb.Ped.Radio.Sal.Pú.)
Área (Departamento): Área Obstetricia y Ginecología (Dpto. Cirugía)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.
Exportado de SIDERAL (2022-06-21-09:40:15)
Visitas y descargas
Cases: We analysed the clinical performance during pregnancy of a rapid, lateral-flow immunochromatographic assay for qualitative detection of SARS-CoV-2 IgG/IgM antibodies. We performed a universal screening including 169 patients during their last trimester of pregnancy. We present a series of 14 patients with positive SARS-CoV-2 immunochromatographic assay rapid test result. Immunochromatographic assay results were always confirmed by chemiluminescent microparticle immunoassays for quantitative detection of SARS-CoV-2 IgG and IgM+IgA antibodies as the gold standard. We observed a positive predictive value of 50% and a false positive rate of 50% in pregnant women, involving a significantly lower diagnostic performance than reported in non-pregnant patients.
Discussion: Our data suggest that although immunochromatographic assay rapid tests may be a fast and profitable screening tool for SARS-CoV-2 infection, they may have a high false positive rate and low positive predictive value in pregnant women. Therefore, immunochromatographic assay for qualitative detection of SARS-CoV-2 IgG/IgM antibodies must be verified by other test in pregnant patients.
Idioma: Inglés
DOI: 10.1177/0004563220980495
Año: 2020
Publicado en: ANNALS OF CLINICAL BIOCHEMISTRY 58, 2 (2020), 149-152
ISSN: 0004-5632
Factor impacto JCR: 2.057 (2020)
Categ. JCR: MEDICAL LABORATORY TECHNOLOGY rank: 20 / 29 = 0.69 (2020) - Q3 - T3
Factor impacto SCIMAGO: 0.6 - Medicine (miscellaneous) (Q2) - Clinical Biochemistry (Q2)
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/CM18-00202
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/JR19-00006
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Microbiología (Dpto. Microb.Ped.Radio.Sal.Pú.)
Área (Departamento): Área Obstetricia y Ginecología (Dpto. Cirugía)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.Exportado de SIDERAL (2022-06-21-09:40:15)
Enlace permanente:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Artículos
Registro creado el 2021-01-15, última modificación el 2022-06-21